LatticeMLS
Menu

Module HEME-15 · Version 1.0

Hemolytic and Other Nonneoplastic Red-Cell Disorders

Use an integrated laboratory pattern to recognize increased red-cell destruction, separate it from specimen hemolysis, and choose bounded follow-up.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Advanced medical laboratory science learners and practicing laboratory professionals who interpret CBC, chemistry, urine, blood-bank, and peripheral-smear findings.

Learning objectives

  • Distinguish laboratory evidence of hemolysis from in vitro specimen hemolysis.
  • Organize intravascular versus extravascular tendencies without treating them as absolute.
  • Select direct antiglobulin test (DAT), enzyme, membrane, hemoglobin, or complement-related follow-up based on the pattern.

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

13 sources

  1. 1. Turner J, Parsi M, Badireddy M. Anemia. StatPearls [Internet]. Updated 2023.

    Source note · peer-reviewed literature

  2. 2. Panchal H, Tiwari AK. Laboratory Evaluation of Immune Hemolytic Anemias. StatPearls [Internet]. Updated 2024.

    Source note · peer-reviewed literature

  3. 3. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease Markers. 2015;2015:635670.

    Source note · peer-reviewed literature

  4. 4. Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. British Journal of Haematology. 2017;176:395-411.

    Source note · professional society guidance

  5. 5. Zini G, d'Onofrio G, Erber WN, et al. 2021 update of ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. International Journal of Laboratory Hematology. 2021;43:1307-1312.

    Source note · consensus standard

  6. 6. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for diagnosis and monitoring of PNH by flow cytometry. Cytometry Part B Clinical Cytometry. 2010;78B:211-230.

    Source note · professional society guidance

  7. 7. Oldaker TA, Wallace PK, Barnett D, et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in PNH, Part 4. Cytometry Part B Clinical Cytometry. 2018;94:49-66.

    Source note · professional society guidance

  8. 8. Clinical and Laboratory Standards Institute. EP07: Interference Testing in Clinical Chemistry. 3rd ed. 2018, reaffirmed 2022.

    Source note · consensus standard

  9. 9. Clinical and Laboratory Standards Institute. Clinical Laboratory Testing Interference. CLSI Insights Blog. 2023.

    Source note · consensus standard

  10. 10. 42 CFR 493.1251, Standard: Procedure manual.

    Source note · federal regulation

  11. 11. 42 CFR 493.1253, Standard: Establishment and verification of performance specifications.

    Source note · federal regulation

  12. 12. College of American Pathologists. All Common Checklist. Laboratory Accreditation Program, laboratory adopted edition.

    Source note · accreditation standard

  13. 13. Mayo Clinic Laboratories. Reticulocyte Profile, Blood, test RETB.

    Source note · manufacturer labeling